VivoSim Labs, Inc. (VIVS): Capital Expenditures
$0
Year ended 2026-03-31
$23.0K
Trailing 12 months to 2026-06-30
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $0 | -100.0% | 2026-07-14, From 2025-04-01 |
| 2025-03-31 | $13.0K | -69.0% | 2026-07-14, From 2024-04-01 |
| 2024-03-31 | $42.0K | -89.4% | 2025-06-05, From 2023-04-01 |
| 2023-03-31 | $396.0K | -3.2% | 2024-05-31, From 2022-04-01 |
| 2022-03-31 | $409.0K | +1.0% | 2023-07-14, From 2021-04-01 |
| 2021-03-31 | $405.0K | n/a | 2022-06-10, From 2020-04-01 |
| 2020-03-31 | $0 | -100.0% | 2021-06-15, From 2019-04-01 |
| 2019-03-31 | $79.0K | -65.0% | 2020-05-28, From 2018-04-01 |
| 2018-03-31 | $226.0K | -83.3% | 2019-06-03, From 2017-04-01 |
| 2017-03-31 | $1.35M | -36.0% | 2018-05-31, From 2016-04-01 |
| 2016-03-31 | $2.11M | +39.4% | 2018-05-31, From 2015-04-01 |
| 2015-03-31 | $1.52M | +447.7% | 2017-06-07, From 2014-04-01 |
| 2014-03-31 | $277.0K | n/a | 2016-06-09, From 2013-04-01 |
| No annual figure between 2012-12-31 and 2014-03-31. | |||
| 2012-12-31 | $357.0K | +676.1% | 2015-06-09, From 2012-01-01 |
| 2011-12-31 | $46.0K | n/a | 2014-06-10, From 2011-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $0 | -100.0% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $77.0K | +18.5% |
| AIM ImmunoTech Inc. (AIM) | 2024-12-31 | $18.0K | n/a |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $1.04M | n/a |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $107.0K | n/m |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $44.0K | -45.0% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $196.0K | +653.8% |
| Prokidney Corp. (PROK) | 2025-12-31 | $15.20M | -48.5% |
| Pluri Inc. (PLUR) | 2026-06-30 | $633.0K | -60.9% |
Compare VIVS, ATYR, AIM, INMB side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗